Distributor inventory | Tablet

Type 2 diabetes mellitus to improve glycaemic control along with diet and exercise; used alone or in combination with other antidiabetic medicines (e.g., metformin, sulfonylurea, insulin) as prescribed.

Vildagliptin is a DPP-4 inhibitor. It increases levels of incretin hormones (GLP-1 and GIP), which enhance glucose-dependent insulin release and reduce glucagon secretion, lowering blood glucose mainly after meals with a low risk of hypoglycaemia when used alone.

Oral tablet. Take exactly as prescribed, preferably at the same time each day, with or without food. Common regimens: 50 mg once daily or 50 mg twice daily depending on combination therapy and kidney function; do not stop without medical advice.

Headache, dizziness, nausea, vomiting, diarrhoea, abdominal pain, constipation, tremor, peripheral oedema, rash, upper respiratory tract infection, hypoglycaemia (especially with sulfonylurea/insulin), increased liver enzymes

Not for type 1 diabetes or diabetic ketoacidosis. Use with caution in kidney impairment (dose adjustment may be needed); avoid/contraindicated in severe hepatic impairment. Monitor liver function before starting and periodically; stop if jaundice or persistent significant rise in transaminases. Rare risk of pancreatitis—seek urgent care for severe persistent abdominal pain. Hypersensitivity reactions (angioedema, rash) may occur. Use caution in heart failure; follow physician advice. Not recommended in children unless prescribed by a specialist.

Insulin and sulfonylureas (increased risk of hypoglycaemia), ACE inhibitors (may increase risk of angioedema), corticosteroids/thiazide diuretics/sympathomimetics (may raise blood glucose and reduce control).

Store below 25°C in a cool, dry place. Protect from moisture and light. Keep out of reach of children.

Galvus 50 Tablet, Vysov-M 50 Tablet, Vilda 50 Tablet, Vildaglip 50 Tablet, Vildapin 50 Tablet